uniQure (QURE) has issued an announcement.
On July 22, 2024, uniQure completed the sale of its Lexington Facility, along with certain assets and liabilities. The deal with Genezen Holdings included receiving $12.5 million in Series C preferred stock and a $12.5 million convertible promissory note, both yielding an 8% annual return. Additionally, uniQure entered into agreements ensuring Genezen will manufacture and supply HEMGENIX® for uniQure, along with other development services. The transaction details, including the Asset Purchase Agreement, will feature in uniQure’s upcoming quarterly report, while a press release about the closure of the deal was also issued.
See more data about QURE stock on TipRanks’ Stock Analysis page.
